Trump Executive Order Sparks Medical Marijuana Research Boost

By John Pranay (Editor)

President Donald J. Trump has signed an Executive Order to improve medical marijuana and cannabidiol research in the United States. The move aims to better inform patients and doctors about the potential medical uses of marijuana and CBD products. The order directs the Attorney General to expedite the rescheduling of marijuana to Schedule III of the Controlled Substance Act (CSA) and allows for enhanced research on hemp-derived cannabinoid products.

The Executive Order is a significant step towards recognizing the medical use of marijuana and improving research on its safety and efficacy. The move follows a 2023 recommendation from the Department of Health and Human Services (HHS) that recognized marijuana as having a currently accepted medical use. The FDA has also reviewed the landscape of medical use of marijuana and found credible scientific support for its use to treat anorexia, nausea and vomiting, and pain.

The order directs the White House Deputy Chief of Staff to work with Congress to allow Americans to benefit from access to appropriate full-spectrum CBD products while restricting the sale of products that pose serious health risks. This move is expected to improve patient symptoms for common ailments and provide better guidance for doctors on prescribing and utilizing medical marijuana.

• 2023: The Department of Health and Human Services (HHS) recommends rescheduling marijuana to Schedule III of the Controlled Substance Act (CSA), recognizing its currently accepted medical use.

• 2025: President Donald J. Trump signs an Executive Order to improve medical marijuana and cannabidiol research, directing the Attorney General to expedite the rescheduling of marijuana and allowing for enhanced research on hemp-derived cannabinoid products.

The Executive Order is expected to impact millions of Americans who use medical marijuana to manage chronic pain, nausea and vomiting, and other medical conditions. According to the FDA, 6 in 10 people who use medical marijuana report doing so to manage pain, and 1 in 10 seniors used marijuana in the last year. The order also aims to improve access to CBD products, which are frequently used by Americans to manage common health conditions.

The lack of appropriate research on medical marijuana and consequent lack of FDA approval has left American patients and doctors without adequate guidance on prescribing and utilizing medical marijuana. The Executive Order aims to address this issue by improving research on safety and efficacy and providing better information on hemp-derived cannabinoid products.

This Executive Order marks a significant shift in the Federal government's approach to medical marijuana and CBD research. By recognizing the medical use of marijuana and improving research on its safety and efficacy, the order aims to provide better guidance for doctors and patients. However, it also raises concerns about the potential risks associated with increased access to CBD products, particularly full-spectrum CBD products that pose serious health risks. Crucially, this overlooks the need for further research on the long-term effects of CBD use, particularly among vulnerable populations such as seniors and veterans.

Our internal tone gauge currently reads: Bullish for this development.

1. INCREASING MEDICAL MARIJUANA AND CANNABIDIOL RESEARCH — https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/

2. President Trump Issues Executive Order Rescheduling Marijuana To Recognize For The First Time That Marijuana Has A Currently Accepted Medical Use — https://goldrushcam.com/sierrasuntimes/index.php/news/local-news/73849-president-trump-issues-executive-order-rescheduling-marijuana-to-recognize-for-the-first-time-that-marijuana-has-a-currently-accepted-medical-use

3. Trump Boosts Medical Marijuana, CBD Research — https://www.miragenews.com/trump-boosts-medical-marijuana-cbd-research-1593160/

Methodology: This analysis combines real-time data aggregation from manually selected global sources with advanced AI synthesis, engineered to provide neutral and data-driven insights.